Recent advances in isatin hybrids as potential anticancer agents

Volume: 353, Issue: 3, Pages: 1900367 - 1900367
Published: Jan 21, 2020
Abstract
The isatin framework is a useful template for the development of novel anticancer agents. This is exemplified by the fact that several isatin-based anticancer agents, such as semaxanib, sunitinib, nintedanib, and hesperadin, are already in use or under clinical trials for the treatment of diverse kinds of cancers. Isatin-based hybrids could be obtained by incorporating other anticancer pharmacophores into the isatin skeleton and they have the...
Paper Details
Title
Recent advances in isatin hybrids as potential anticancer agents
Published Date
Jan 21, 2020
Volume
353
Issue
3
Pages
1900367 - 1900367
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.